Sadhana Jackson

List of Publications by Year
in descending order

17	316	1040056 9	1199594 12
papers	citations	h-index	g-index

17	17	17	502
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting WNT Signaling for Multifaceted Glioblastoma Therapy. Frontiers in Cellular Neuroscience, 2017, 11, 318.	3.7	79
2	The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the CNS, 2018, 15, 2.	5.0	55
3	Model systems for studying the blood-brain barrier: Applications and challenges. Biomaterials, 2019, 214, 119217.	11.4	50
4	Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimerâ€™s disease. Neuro-Oncology, 2017, 19, 1173-1182.	1.2	28
5	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma. Cancers, 2021, 13, 5280.	3.7	26
6	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery, 2019, 84, 945-953.	1.1	24
7	Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma. Neuro-Oncology, 2021, 23, 1481-1493.	1.2	18
8	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-Oncology Advances, 2020, 2, vdaa095.	0.7	15
9	Adenosine A2A Receptor Activation Enhances Bloodâ€“Tumor Barrier Permeability in a Rodent Glioma Model. Molecular Cancer Research, 2021, 19, 2081-2095.	3.4	10
10	SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. Neuro-Oncology, 2021, 23, 1845-1858.	1.2	8
11	Grassroots efforts to end structural racism throughout the US National Institutes of Health. Nature Medicine, 2022, 28, 223-224.	30.7	2
12	RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1. Neuro-Oncology, 2018, 20, vi237-vi237.	1.2	1
13	TMIC-49. ACTIVATION OF THE Wnt/Î²-CATENIN SIGNALING PATHWAY IN GLIOMA STEM CELLS IMPACTS ENDOTHELIAL CELL-CELL INTERACTION. Neuro-Oncology, 2018, 20, vi267-vi267.	1.2	0
14	High-risk Medulloblastomaâ€”Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity. JAMA Oncology, 2021, 7, 1322.	7.1	0
15	STEM-23. INHIBITING PROTEIN PHOSPHATASE 2A INCREASES THE ANTITUMOR EFFECT OF PROTEIN ARGININE METHYLTRANSFERASE 5 INHIBITION IN MODELS OF GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii201-ii201.	1.2	0
16	STEM-03. WAVE1 KNOCKDOWN ENHANCES THE ANTITUMOR EFFICACY IN PRIMARY GLIOBLASTOMA NEUROSPHERES. Neuro-Oncology, 2020, 22, ii196-ii197.	1.2	0
17	Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back. Neuro-Oncology, 2022, , .	1.2	0